Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JLC056
- Development stage
- Preclinical
- Lead developer
- Jecho Laboratories
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JLC056 is a bispecific antibody-drug conjugate (ADC) being developed by Jecho Laboratories. It is designed to simultaneously target Tissue Factor (TF) and Epidermal Growth Factor Receptor (EGFR), two proteins that are frequently overexpressed in a variety of solid tumors. By dual-targeting these antigens, JLC056 aims to deliver a cytotoxic payload specifically to tumor cells, potentially enhancing therapeutic efficacy and reducing off-target toxicity compared to monospecific ADCs. This approach may also help overcome resistance mechanisms associated with single-target therapies. JLC056 is currently in the IND-enabling stage of development for oncology indications.
02
Targets
F3 (Tissue factor)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on JLC056.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JLC056.